CellSource to Launch Enhanced Adipose-Derived Stem Cell Extraction Technology; Shares Down 7%
CellSource (TYO:4880) will offer an updated extraction technology in October for adipose-derived cultured stem cells, which could improve the removal of senescent cells and enhance overall cell quality.
The updated extraction technology was inspired by the development of extracellular vesicle manufacturing technology, according to its Thursday filing.
The development reflects ongoing efforts to update services based on insights from cell and blood processing research and collaborations.
CellSource's shares lost over 7% in early trade.
Price (JPY): $1283.00, Change: $-98, Percent Change: -7.10%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.